Company intelligence / Profile preview

Jafral

Ownership: Private
Development stage: Commercial

Overview

Jafral is a leading CMO/CRO specializing in the development and GMP/non-GMP manufacturing of bacteriophages, plasmid DNA, and proteins. The company supports biopharma partners with process development, analytical method development, cell/virus banking, API/drug substance production, drug product formulation, contract analytical testing, stability studies, and large-scale phage production. It has contributed to gene therapy clinical trials as a manufacturing partner but does not have its own proprietary therapeutics pipeline

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage therapyPlasmid DNAProteinBiologic
Industry: Contract Manufacturing Organization

Partnerships

NexaBiome (industrial-scale phage production partnership)

Beyond the preview

Go deeper on Jafral.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jafral.

Explore the full profile